Drug Profile
COVID-2019 immune globulins - Emergent BioSolutions
Alternative Names: Anti-coronavirus hIVIG - Emergent BioSolutions; Anti-coronavirus hyperimmune intravenous immunoglobulin - Emergent BioSolutions; Anti-SARS-CoV-2 immune globulin intravenous (Human) - Emergent BioSolutions; COVID-HIG - Emergent BioSolutions; NP-028Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Emergent BioSolutions
- Developer Emergent BioSolutions; National Institute of Allergy and Infectious Diseases
- Class Antivirals; Immunoglobulins; Polyclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III COVID 2019 infections
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention, In volunteers) in USA (IV, Infusion)
- 31 May 2022 Emergent BioSolutions completes a phase I trial in Healthy volunteers in USA (IV, IM, SC) (NCT05142306)
- 07 Dec 2021 Emergent BioSolutions initiates enrolment in a phase-I trial for COVID-2019 infections (In volunteers) in USA (IV) (NCT05142306)